Pegilodecakin

DB15162InvestigationalProtein Based Therapies

Pegilodecakin is under investigation in clinical trial NCT03382912 (Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer).

Mechanism: Pharmacologically active on Interleukin-10 receptor subunit beta and Interleukin-10 receptor subunit alpha
Curator reviewed
Also known as: INTERLEUKIN 10 (SYNTHETIC HUMAN), DIMER, N-TERMINAL 5-KILODALTON PEGYLATED
Code names: AM-0010 · LY-3500518

Resolves to

Compound

UNII5Z9850I25FCAS1966111-35-2

Targets

Q08334IL10RBQ13651IL10RA

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pegilodecakin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account